356 related articles for article (PubMed ID: 23850491)
1. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
[TBL] [Abstract][Full Text] [Related]
2. Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme.
Cavanagh TT; Holle LM
Cancer Biol Ther; 2014 Mar; 15(3):263-5. PubMed ID: 24352098
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
[TBL] [Abstract][Full Text] [Related]
4. Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.
van Putten EH; Dirven CM; van den Bent MJ; Lamfers ML
Future Oncol; 2010 Nov; 6(11):1691-710. PubMed ID: 21142657
[TBL] [Abstract][Full Text] [Related]
5. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.
Immonen A; Vapalahti M; Tyynelä K; Hurskainen H; Sandmair A; Vanninen R; Langford G; Murray N; Ylä-Herttuala S
Mol Ther; 2004 Nov; 10(5):967-72. PubMed ID: 15509514
[TBL] [Abstract][Full Text] [Related]
6. Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma.
Düzgünes N
Curr Opin Mol Ther; 2008 Apr; 10(2):187-95. PubMed ID: 18386231
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
[TBL] [Abstract][Full Text] [Related]
8. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses.
Sandmair AM; Loimas S; Puranen P; Immonen A; Kossila M; Puranen M; Hurskainen H; Tyynelä K; Turunen M; Vanninen R; Lehtolainen P; Paljärvi L; Johansson R; Vapalahti M; Ylä-Herttuala S
Hum Gene Ther; 2000 Nov; 11(16):2197-205. PubMed ID: 11084677
[TBL] [Abstract][Full Text] [Related]
9. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
[TBL] [Abstract][Full Text] [Related]
11. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
12. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
13. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
Rainov NG
Hum Gene Ther; 2000 Nov; 11(17):2389-401. PubMed ID: 11096443
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging.
Maron A; Gustin T; Le Roux A; Mottet I; Dedieu JF; Brion JP; Demeure R; Perricaudet M; Octave JN
Gene Ther; 1996 Apr; 3(4):315-22. PubMed ID: 8732163
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir.
Smitt PS; Driesse M; Wolbers J; Kros M; Avezaat C
Mol Ther; 2003 Jun; 7(6):851-8. PubMed ID: 12788659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
